Heart and Estrogen/progestin Replacement Study

Heart and Estrogen/progestin Replacement Study
Name	Heart and Estrogen/progestin Replacement Study
Acronym	HERS
Phase	Randomized Controlled Trial
Start date	1993
Completion date	2002
Study type	Secondary prevention cardiovascular trial
Interventions	Conjugated equine estrogens with medroxyprogesterone acetate
Primary outcome	Coronary heart disease events
Funding	National Institutes of Health

Heart and Estrogen/progestin Replacement Study

The Heart and Estrogen/progestin Replacement Study was a randomized, placebo-controlled clinical trial evaluating combined conjugated equine estrogens and medroxyprogesterone acetate for secondary prevention of coronary heart disease in postmenopausal women. Conducted in the United States and Canada, the trial enrolled women with established coronary disease and tested whether hormone therapy reduced myocardial infarction, coronary death, or other ischemic events. The study's results influenced guidelines from major organizations and redirected research priorities in cardiovascular prevention, women's health, and hormone replacement therapy.

Background

In the late 20th century, observational studies and cohort analyses suggested estrogen might reduce cardiovascular risk, prompting leaders such as the National Institutes of Health, investigators affiliated with Johns Hopkins University, and clinicians at the Framingham Heart Study to prioritize randomized trials. Influential figures in epidemiology and cardiology, including researchers affiliated with the American Heart Association and the Women's Health Initiative, debated the role of hormone replacement after menopause. Prior trials and meta-analyses involving investigators from institutions like Harvard University, Yale University, and Stanford University underscored the need for definitive randomized data. Political and regulatory actors—such as the Food and Drug Administration and congressional committees—also scrutinized hormone therapy's claims following publicity around products from pharmaceutical firms like Wyeth and corporate litigation involving menopausal therapies.

Study Design and Methods

HERS was designed as a multicenter, randomized, double-blind, placebo-controlled trial led by academic centers including Washington University in St. Louis and the University of Minnesota. Eligible participants were postmenopausal women with angiographically confirmed coronary artery disease identified through referrals from cardiology practices associated with institutions such as Massachusetts General Hospital and Mayo Clinic. The active regimen combined conjugated equine estrogens with medroxyprogesterone acetate; placebo arms mirrored pharmaceutical-controlled designs used in trials affiliated with Columbia University and Duke University Medical Center. Endpoints included nonfatal myocardial infarction and coronary death, adjudicated by committees comprising experts who had worked with groups like the European Society of Cardiology and the Canadian Cardiovascular Society. Randomization, data monitoring, and interim analyses followed standards articulated by the Data Safety Monitoring Board frameworks used in trials at National Institutes of Health networks and resembled statistical plans from large outcome trials at University of California, San Francisco.

Results

Primary results showed no reduction in overall coronary events with hormone therapy over the trial period, and an early increase in risk during the first year of treatment. Major outcomes—myocardial infarction, coronary death, and composite ischemic events—were reported by investigators who later presented findings at meetings of the American College of Cardiology, the European Atherosclerosis Society, and the World Congress of Cardiology. Secondary analyses stratified by age, time since menopause, and prior revascularization were performed by teams affiliated with Princeton University and University of Pennsylvania. The null primary outcome contrasted with earlier observational signals reported by cohorts such as the Nurses' Health Study and prompted rapid reappraisal by guideline authors from the National Heart, Lung, and Blood Institute and practice committees within the American College of Physicians.

Adverse Events and Safety

Safety monitoring identified increased risks of venous thromboembolism, stroke, and gallbladder disease in subsets of participants, paralleling adverse event profiles seen in pharmacovigilance reports submitted to the Food and Drug Administration and regulatory reviews at agencies like Health Canada. Site investigators from centers including Cedars-Sinai Medical Center and University of California, San Diego reported procedure-related complications and hospitalizations adjudicated by independent panels modeled after review boards at New York University Langone Health. The trial's safety signals contributed to boxed warnings, risk communication from manufacturers such as Wyeth and later risk–benefit discussions at meetings of the International Menopause Society.

Interpretation and Impact

HERS demonstrated that combined estrogen–progestin therapy did not confer cardiovascular protection in women with established coronary disease and might increase short-term risk, a finding that altered clinical practice across cardiology and gynecology. Professional societies including the American Heart Association and the North American Menopause Society updated recommendations, while academic centers like Oxford University and Cambridge University incorporated the evidence into curricula. Health policy actors in agencies such as the Centers for Disease Control and Prevention and payers in systems like Medicare (United States) and provincial health ministries in Ontario revised guidance on hormone replacement. Media coverage in outlets associated with editorial boards like the New York Times and scientific reporting by journals such as The New England Journal of Medicine amplified the trial's conclusions.

Subsequent Research and Legacy

HERS prompted further randomized trials, most notably the Women's Health Initiative, and spawned mechanistic research at laboratories in institutions like Columbia University, University of Texas Southwestern Medical Center, and Scripps Research. Secondary analyses and pooled meta-analyses by consortia including investigators from Imperial College London and the Karolinska Institutet refined understanding of age- and time-since-menopause interactions. Litigation, regulatory changes, and shifts in pharmaceutical strategy by firms including Pfizer and Merck & Co. followed the new evidence landscape. The trial remains a landmark in cardiology and women's health, cited in guidelines from the World Health Organization and teaching materials at medical schools such as Johns Hopkins University School of Medicine and Harvard Medical School.

Category:Clinical trials Category:Cardiology Category:Menopause